Vistagen Therapeutics Announces Topline Phase 2 Results for Fasedienol in SAD

What Happened
Vistagen Therapeutics (VTGN) announced on August 6, 2026 the topline results from a three‑arm, multicenter, randomized, double‑blind, placebo‑controlled exploratory Phase 2 study (N=61) of fasedienol nasal spray for acute treatment of public‑speaking‑induced anxiety in adults with social anxiety disorder (SAD). The trial compared two 3.2 µg doses given 10 minutes apart (repeat dose) to a single 3.2 µg dose and placebo. The study met its safety objective (no new safety findings) and showed numerical separation from placebo on the primary endpoint (change in SUDS score V2 to V3), though differences were not statistically significant for the overall population.

Key Details

• Study size: N = 61; design = three‑arm randomized, double‑blind, placebo‑controlled exploratory Phase 2.
• Dose tested: 3.2 µg single dose vs two 3.2 µg doses administered 10 minutes apart vs placebo.
• Safety: Repeat dosing produced safety and tolerability comparable to single dosing; no new safety signals.
• Efficacy signals: Overall SUDS change showed numerical separation vs placebo but not statistically significant. In the prespecified subgroup with very severe SAD (LSAS ≥95), the single‑dose and pooled fasedienol arms showed nominal statistical significance vs placebo; repeat‑dose showed a larger numeric effect but higher p‑value due to small sample size. Responder rates (CGI‑I, PGI‑C) were directionally higher for fasedienol; repeat‑dose responder rates were >2× placebo overall and ≥4× placebo in the very severe subgroup. An anticipatory‑anxiety analysis showed larger SUDS decreases for repeat‑dose and pooled fasedienol (nominal significance).

Why It Matters
For investors, the filing shows a favorable safety profile for repeat dosing and early efficacy signals—particularly in patients with very severe SAD—that are consistent with prior post‑hoc Phase 3 findings (PALISADE‑4). However, this was an exploratory, small trial not powered for definitive statistical conclusions; the company cautions results are preliminary and subject to change pending full data analysis. These topline findings may inform upcoming discussions with the FDA about a potential registrational pathway, but there is no assurance they will support approval or commercial success; continued development will depend on larger, adequately powered studies and the company’s ability to fund further trials.